NCT03169543

Brief Summary

From 40 to 60% of patients with depression experience a rapid and significant improvement of mood with one night of sleep deprivation (SD). The neural mechanisms underlying this effect have not been elucidated. Recent advances in functional neuroimaging have provided new opportunities to investigate state changes in regional brain function, along with a better understanding of the neural networks affected by depression and SD. Here we propose to study a group of N=48 antidepressant-free male and female patients with current depression symptom and N=12 healthy controls with no history of mood disorders before and after SD to provide mechanistic insight into the neural substrates underlying the antidepressant effects of SD. We hypothesize that SD-induced concurrent functional activity and connectivity changes in multiple brain networks related to different depressive symptom dimensions including emotion regulation, attention, arousal, self-referential, and reward processing will underlie the rapid and transient antidepressant effects of SD. Using an ABA design, multimodal brain imaging along with more traditional electroencephalographic (EEG) and neurobehavioral testing data will be acquired at baseline after normal sleep, during one night of total SD, and after one night of recovery sleep using a 5-day in laboratory protocol during which subjects will be continuously monitored by trained staff.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2016

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

May 24, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 30, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2020

Completed
Last Updated

March 25, 2020

Status Verified

March 1, 2020

Enrollment Period

3.9 years

First QC Date

May 24, 2017

Last Update Submit

March 24, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in HAMD-NOW scores

    Total score on a modified Hamilton Depression Inventory that assesses mood symptoms in the moment.

    Each morning for 4 days

Secondary Outcomes (1)

  • Change in neuroimaging

    Each morning for 3 days

Study Arms (1)

Sleep deprivation

EXPERIMENTAL

36-hours of total sleep deprivation

Behavioral: Sleep deprivation

Interventions

36-hours total sleep deprivation

Sleep deprivation

Eligibility Criteria

Age21 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Current depression as assessed on the HDRS-17 (for depressed group only)
  • Body mass index within 15% of normal
  • Stable, normally-timed sleep-wake cycle defined by: a. Habitual nocturnal sleep duration between 6h and 9h. b. Habitual morning awakening between 0600h and 0800h.
  • Able to comprehend English, as all questionnaires are in this language
  • Ability to provide informed consent

You may not qualify if:

  • Shift work, transmeridian travel or irregular sleep/wake routine in past 60 days
  • A sleep disorder other than insomnia
  • History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders
  • No history of depression for the control group.
  • Alcohol or drug abuse in the past year
  • A current smoker.
  • Any acute or chronic, debilitating medical conditions, epilepsy, or thyroid disease.
  • Metallic implants, pacemakers or tattoos, or history of working in metal workshops.
  • Claustrophobic, or intolerant of the scanner environment.
  • For women, pregnancy will exclude participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Depressive Disorder

Condition Hierarchy (Ancestors)

Mood DisordersMental Disorders

Study Officials

  • Philip Gehrman, PhD

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2017

First Posted

May 30, 2017

Study Start

April 1, 2016

Primary Completion

February 28, 2020

Study Completion

February 28, 2020

Last Updated

March 25, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations